Back to Search
CHRISTIAN SESSA, D.O.
D.O.
Family Medicine Physician
NPI: 1730123332IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
02001910A(IN)
CMS Specialties
PrimaryFAMILY PRACTICE
Education
NEW YORK COLLEGE OF OSTEO MEDICINE OF NEW YORK INSTITUTE OF TECHNOLOGY
Class of 1993
Research & Publications (20)
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.
PMID 19114300·Eur J Cancer·2009
3-trial
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
PMID 19419856·Eur J Cancer·2009
3-trial
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
PMID 18560389·Nat Clin Pract Oncol·2008
6-review
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.
PMID 17150998·Ann Oncol·2007
3-trial
Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.
PMID 16406576·Eur J Cancer·2006
3-trial
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
PMID 15774779·J Clin Oncol·2005
3-trial
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.
PMID 14962724·Eur J Cancer·2004
3-trial
Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex.
PMID 11038034·Ann Oncol·2000
3-trial
Adjuvant therapy for colon cancer: present and perspectives.
PMID 19013023·Cancer Treat Rev·2009
6-review
Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
PMID 19411316·Oncologist·2009
6-review
Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours.
PMID 19190075·Ann Oncol·2009
3-trial
Dramatic improvement in survival after lung transplantation over time: a single center experience.
PMID 19328957·Transplant Proc·2009
8-other
A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function.
PMID 19047125·Clin Cancer Res·2008
3-trial
Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development.
PMID 18024014·Eur J Cancer·2008
6-review
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.
PMID 18640031·Eur J Cancer·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 600 9TH AVE N
SIBLEY, IA 51249 - Phone
- (712) 754-3658
Quick Facts
- NPI
- 1730123332
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 33
- Publications
- 20
Are you this provider?
Claim Your Profile